JP2020526590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526590A5 JP2020526590A5 JP2020522786A JP2020522786A JP2020526590A5 JP 2020526590 A5 JP2020526590 A5 JP 2020526590A5 JP 2020522786 A JP2020522786 A JP 2020522786A JP 2020522786 A JP2020522786 A JP 2020522786A JP 2020526590 A5 JP2020526590 A5 JP 2020526590A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- cell receptor
- seq
- biologically
- autonomously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008875 B cell receptors Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 208000012526 B-cell neoplasm Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17001166 | 2017-07-07 | ||
| EP17001167 | 2017-07-07 | ||
| EP17001167.0 | 2017-07-07 | ||
| EP17001166.2 | 2017-07-07 | ||
| EP18162672.2A EP3424528A1 (de) | 2017-07-07 | 2018-03-19 | Biologische bindemoleküle |
| EP18162672.2 | 2018-03-19 | ||
| PCT/EP2018/068317 WO2019008129A1 (de) | 2017-07-07 | 2018-07-05 | Biologische bindemoleküle |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526590A JP2020526590A (ja) | 2020-08-31 |
| JP2020526590A5 true JP2020526590A5 (enExample) | 2021-08-12 |
| JP7271532B2 JP7271532B2 (ja) | 2023-05-11 |
Family
ID=64500047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522785A Active JP7239575B2 (ja) | 2017-07-07 | 2018-07-05 | サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 |
| JP2020522786A Active JP7271532B2 (ja) | 2017-07-07 | 2018-07-05 | 生物学的結合分子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522785A Active JP7239575B2 (ja) | 2017-07-07 | 2018-07-05 | サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11591391B2 (enExample) |
| EP (4) | EP3424527A1 (enExample) |
| JP (2) | JP7239575B2 (enExample) |
| CA (1) | CA3070848A1 (enExample) |
| WO (2) | WO2019008128A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424527A1 (de) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostisches verfahren |
| EP3733709A1 (de) * | 2019-05-02 | 2020-11-04 | AVA Lifescience | Biologische bindemoleküle |
| WO2020221463A1 (de) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Verfahren zur selektion biologischer bindemoleküle |
| CA3148214A1 (en) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Antigent binding domains and uses therefor |
| CA3229193A1 (en) * | 2021-08-18 | 2023-02-23 | Marco RUELLA | Compositions and methods for chimeric antigen receptors specific to b cell receptors |
| EP4227321A1 (en) | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
| US20250145706A1 (en) | 2022-02-10 | 2025-05-08 | Sinabiosolution Gmbh | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof |
| JP2025530980A (ja) * | 2022-07-25 | 2025-09-19 | サインエイバイオソリューションズ ゲーエムベーハー | 慢性リンパ性白血病のｂ細胞受容体を標的とするヒト化キメラ抗原受容体およびその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| SG11201405130UA (en) * | 2012-02-24 | 2014-11-27 | Stemcentrx Inc | Anti sez6 antibodies and methods of use |
| US9770504B2 (en) * | 2013-05-03 | 2017-09-26 | The Board Of Regents Of The University Of Texas System | Generating peptoid vaccines |
| MX377339B (es) * | 2013-08-28 | 2025-03-06 | Abbvie Stemcentrx Llc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. |
| EP3424527A1 (de) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostisches verfahren |
-
2018
- 2018-03-19 EP EP18162666.4A patent/EP3424527A1/de not_active Withdrawn
- 2018-03-19 EP EP18162672.2A patent/EP3424528A1/de not_active Withdrawn
- 2018-07-05 JP JP2020522785A patent/JP7239575B2/ja active Active
- 2018-07-05 EP EP18746104.1A patent/EP3615073A1/de active Pending
- 2018-07-05 US US16/625,756 patent/US11591391B2/en active Active
- 2018-07-05 JP JP2020522786A patent/JP7271532B2/ja active Active
- 2018-07-05 WO PCT/EP2018/068316 patent/WO2019008128A1/de not_active Ceased
- 2018-07-05 WO PCT/EP2018/068317 patent/WO2019008129A1/de not_active Ceased
- 2018-07-05 CA CA3070848A patent/CA3070848A1/en active Pending
- 2018-07-05 EP EP18746103.3A patent/EP3615072A1/de active Pending
- 2018-07-05 US US16/625,754 patent/US11634487B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526590A5 (enExample) | ||
| CY1124944T1 (el) | Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| JP2020018311A5 (enExample) | ||
| RU2014149553A (ru) | Биспецифические анти-vegf/анти-ang-2 антитела | |
| JP2019522490A5 (enExample) | ||
| JP2020527727A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| MX2020009121A (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de produccion de anticuerpos anti-sirpa v1. | |
| JP2014518615A5 (enExample) | ||
| JP2017029157A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| RU2017125758A (ru) | Антитела к с5 и способы их применения | |
| CN114502591A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| AR069501A1 (es) | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) | |
| CO6331370A2 (es) | Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos | |
| JP2010506596A5 (enExample) | ||
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2018107427A (ru) | Однодоменное антитело и его производные белки к лиганду-1 белка программируемой смерти клеток(pdli) | |
| RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| JP2014516026A5 (enExample) | ||
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью |